Advertisement

Topics

A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer

20:00 EDT 31 Jul 2017 | AAAS

(Baylor College of Medicine) A phase II clinical trial of neratinib in patients with metastatic breast cancer carrying a HER2 mutation produces encouraging results in that about 30 percent of patients and a promising diagnostic tool for metastatic breast cancer.

Original Article: A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer

NEXT ARTICLE

More From BioPortfolio on "A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...